Thyroid Uptake of Technegas during V/Q Scintigraphy in Graves Disease

2010 ◽  
Vol 123 (5) ◽  
pp. e3-e4
Author(s):  
Andrew E.H. Tan ◽  
Uei Pua
Keyword(s):  
Graves Disease ◽  
Thyroid Uptake

Predictive value of pyramidal lobe, percentage thyroid uptake and age for ablation outcome after 15 mCi fixed dose of radioiodine-131 in Graves′ disease

2015 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
Maseeh uz Zaman ◽  
Nosheen Fatima ◽  
Unaiza Zaman ◽  
Zafar Sajjad ◽  
Rabia Tahseen ◽  
...  
Keyword(s):  
Predictive Value ◽  
Fixed Dose ◽  
Graves Disease ◽  
Thyroid Uptake ◽  
Pyramidal Lobe

Factitious thyrotoxicosis: how to find it

Diagnosis ◽  
2020 ◽  
Vol 7 (2) ◽  
pp. 141-145
Author(s):  
Pakaworn Vorasart ◽  
Chutintorn Sriphrapradang
Keyword(s):  
Radioactive Iodine ◽  
Graves Disease ◽  
Case Presentation ◽  
Thyroglobulin Antibodies ◽  
Definitive Therapy ◽  
Thyroid Uptake ◽  
Thyroid Hormone Levels ◽  
Difficult Challenge

AbstractBackgroundAlthough the most common cause of thyrotoxicosis is Graves’ disease, the determination of the cause of thyrotoxicosis is important for establishing appropriate management. Diagnosis of surreptitious ingestion of thyroid hormones or factitious thyrotoxicosis often presents a difficult challenge especially in a patient with previously diagnosed Graves’ disease. The objective of this report was to demonstrate various approaches to support the diagnosis of factitious thyrotoxicosis.Case presentationWe describe a patient with underlying Graves’ disease who underwent definitive therapy and needed long-term levothyroxine (LT4) replacement therapy. Later she developed thyrotoxicosis. Although factitious thyrotoxicosis was suspected because of very low thyroid uptake and low thyroglobulin (Tg) levels with the absence of thyroglobulin antibodies (TgAbs), she still refused any medication or substance use. After the administration of bile acid sequestrant, the thyroid hormone levels rapidly returned to normal within 1 month.ConclusionsThe diagnosis of factitious thyrotoxicosis is based upon the absence of goiter, suppressed serum Tg level, decreased radioactive iodine (RAI) uptake, and excellent response after cholestyramine treatment.

Somatostatin Receptor Expression in the Thyroid Demonstrated with 111In-Octreotide Scintigraphy

1995 ◽  
Vol 34 (03) ◽  
pp. 100-103 ◽  
Author(s):  
U. Schrell ◽  
M. Buchfelder ◽  
J. Hensen ◽  
J. Wendler ◽  
M. Gramatzki ◽  
...  
Keyword(s):  
Thyroid Gland ◽  
Thyroid Disease ◽  
Endemic Goiter ◽  
Somatostatin Receptor ◽  
Receptor Expression ◽  
Graves Disease ◽  
Tumor Localization ◽  
Thyroid Autonomy ◽  
Thyroid Uptake ◽  
Octreotide Scintigraphy

SummaryNeuroendocrine tumors with somatostatin receptor expression may be localized by 111ln-octreotide scintigraphy. This study examines those thyroid conditions where 111 ln-octreotide uptake could be observed also in the thyroid gland. 26 consecutive patients who underwent 111 ln-octreotide scintigraphy for tumor localization were additionally examined for thyroid disease by sonography and 99mTc-pertechnetate scintigraphy. 12 of these patients had no significant thyroid uptake and had an euthyroid normal-sized thyroid gland. 14 patiens with 111ln thyroid uptakes had endemic goiters, two of them with thyroid autonomy and one with Graves’ disease. Thus, 111 ln-octreotide thyroid uptake was predominantly seen in patients with endemic goiter with or without thyroid autonomy.

Thyroid Uptake of Gallium in Graves?? Disease

1988 ◽  
Vol 13 (9) ◽  
pp. 663-666 ◽  
Author(s):  
JEFFREY C. ALLARD ◽  
VICTOR W. LEE ◽  
PETER FRANKLIN
Keyword(s):  
Graves Disease ◽  
Thyroid Uptake

Comparison of thyroid stimulating activities measured by cyclic AMP production, those by radioiodine uptake in FRTL-5 cells and TSH-binding inhibitory activities in patients with hyperthyroid and euthyroid Graves' diseases

1988 ◽  
Vol 117 (3) ◽  
pp. 365-372 ◽  
Author(s):  
Kanji Kasagi ◽  
Hiroto Hatabu ◽  
Yasutaka Tokuda ◽  
Keisuke Arai ◽  
Yasuhiro Iida ◽  
...  
Keyword(s):  
Graves Disease ◽  
Camp Production ◽  
Thyroid Cells ◽  
Radioiodine Uptake ◽  
Significant Difference ◽  
Thyroid Uptake ◽  
Similar Range ◽  
Inhibitory Activities

Abstract. By using an assay measuring cAMP production in FRTL-5 thyroid cells, thyroid stimulating antibodies (TSab) were detected in all of 15 patients with euthyroid Graves' disease (EG) and of 26 patients with hyperthyroid Graves' disease (HG). There was no significant difference between TSab activities in EG and in HG. In an effort to elucidate why EG patients remain euthyroid in spite of having TSab, we investigated the effect of the patient's crude immunoglobulin fractions on 125I uptake in FRTL-5 thyroid cells, one of the indices of stimulation subsequent to cAMP production. The 125I uptake stimulating (IUS) activity was positive in 46.7% (7/15) of EG patients and 88.5% (23/26) of HG patients, being significantly lower in the former than in the latter (P < 0.02). Although the IUS activities significantly correlated with TSab activities in 41 patients with EG and HG (r = 0.784, P < 0.001), the ratio of IUS to TSab in EG tended to be lower than that in HG. TSH-binding inhibitor immunoglobulins (TBII) activities in EG patients were negative or weakly positive, being significantly lower than those in HG patients (P < 0.001). Thus, the ratios of TBII to both TSab and IUS activities were significantly higher in HG than in EG (P < 0.01, P < 0.001, respectively). The in vitro IUS activities also correlated with TBII activities (r = 0.441, P < 0.001) and in vivo 99mTc thyroid uptake (r = 0.401, P < 0.001) in both EG and HG patients. The EG patients with positive IUS activities displayed smaller goitre size and lower 99m thyroid uptake in comparison to 19 HG patients with a similar range of IUS activities. There was a good correlation between thyroid weight and 99mTc thyroid uptake (r = 0.827, P < 0.001). In conclusion, lower IUS activity and/or smaller goitre size in EG than in HG, which may lead to lower thyroidal uptake of 99mTc and presumably radioiodine in vivo, might be a factor responsible for keeping EG patients euthyroid despite the presence of TSab.

Quantitative thyroid scintigraphy for the differentiation of Graves’ disease and hyperthyroid autoimmune thyroiditis

2004 ◽  
Vol 43 (04) ◽  
pp. 124-128 ◽  
Author(s):  
C. O. Sahlmann ◽  
U. Siefker ◽  
K. Lehmann ◽  
E. Harms ◽  
M. Conrad ◽  
...  
Keyword(s):  
Autoimmune Thyroiditis ◽  
Subclinical Hypothyroidism ◽  
Spontaneous Remission ◽  
Tsh Receptor ◽  
Thyroid Peroxidase ◽  
Graves Disease ◽  
Thyroid Scintigraphy ◽  
Thyroid Uptake ◽  
Reliable Differentiation ◽  
Overt Hyperthyroidism

Summary Aim: The TCTUs (global 99mTc-pertechnetate thyroid uptake under suppression) can be used as an estimate of the iodine clearance of non-TSH regulated tissue. High TCTUs levels are characteristic for Graves’ disease (GD). Decreased uptake has been described in autoimmune thyroiditis (AIT). However, systematically investigated data in a larger series of AIT-patients with subclinical or overt hyperthyroidism are not published so far. The purpose of this study is the evaluation of the TCTUs in the differentiation between AIT and GD in patients with hyperthyroidism. Methods: We determined the TCTUs in 59 patients with untreated hyperthyroid GD and in 51 patients with AIT who had subclinical or manifest hyperthyroidism without medication. Patients with GD were characterized by the presence of hyperthyroidism, decreased echogenicity of the thyroid, elevation of TSH-receptor autoantibodies (TRAb). AIT was defined by a decreased echogenicity of the thyroid, absence of elevated TSH-receptor autoantibodies (TRAb), autoantibodies against the thyroid peroxidase (anti-TPO) and spontaneous remission or development of subclinical hypothyroidism within 3 months. Results: Thyroid volumes of patients with AIT were significantly lower than those of patients with GD (p <0.05). TRAb levels were significantly higher in GD-patients (median: 19.5 U/ml; range: 15.3-35 U/ml) than in AIT-patients (median: 1.3 U/ml; range: 0-4.1 U/ml). 73% (38/59) of patients with GD had elevated anti-TPO levels. In these patients anti-TPO levels (median: 768 U/l; range: 83-6397 U/l) were not significantly different from anti-TPO levels of patients with AIT (median: 834 U/l; range: 107-8675 U/l; p = 0.17). TCTUs values of patients with AIT were significantly lower (p <0.05; median: 0.9%; range: 0.1-3.2%) than those of patients with GD (median: 5.7%; range: 1.9-28.3%). Conclusion: In our patients quantitative thyroid scintigraphy with 99mTcO4 - offered rapid and reliable differentiation between hyperthyroid GD and AIT.

THE INFLUENCE OF PROMINAL ON THYROID FUNCTION IN THE RAT

1955 ◽  
Vol 18 (4) ◽  
pp. 460-461
Author(s):  
F. Schwarz
Keyword(s):  
Thyroid Function ◽  
Barbituric Acid ◽  
Animal Experiments ◽  
Normal Subjects ◽  
Graves Disease ◽  
Unexpected Result ◽  
Experimental Animals ◽  
Thyroid Uptake ◽  
Barbituric Acid Derivatives ◽  
Methyl Phenyl

SUMMARY Prominal (methyl-phenyl-ethyl barbituric acid) and other barbituric acid derivatives can depress the basal metabolic rate in hypermetabolism, in normal subjects and in experimental animals. It has been assumed that, particularly in the case of Graves disease, this is caused by an effect on the diencephalic centres controlling thyroid function (Falta & Fenz, 1937). We were interested in this problem because of the variable results obtained in the clinical treatment of thyrotoxicosis and other hypermetabolic conditions with Prominal. Some animal experiments were therefore done in which, much to our surprise Prominal appeared to raise the I131 uptake of the thyroid gland of rats instead of depressing it. This unexpected result led us to further investigation. Prominal administered for 7 days in a dosage of 15 mg. raised the thyroid uptake of I131 significantly. This was confirmed in three strains of rats. Barbital and phenobarbital appeared to have the same effect as

Sign in / Sign up

Export Citation Format

Share Document